Introduction
============

Sevoflurane is an inhalation anesthetic agent used frequently to induce and maintain outpatient or pediatric anesthesia due to its excellence in hemodynamic stability, less irritation of the mucous membranes and low blood solubility, which causes rapid induction and emergence from anesthesia and controls the anesthesia depth \[[@B1],[@B2]\]. However, it has been reported that there are risks with emergence agitation, the incidence rate of which is particularly high in children, ranging from 30 to 80% of those undergoing general anesthesia with sevoflurane. There have been many studies on the causes of emergence agitation and/or the preventive effects against emergence agitation, but the pathogenesis and preventive treatments are not completely understood.

Ketamine is an effective drug for sedation, analgesia and amnesia. Kararmaz et al. \[[@B3]\] administered 6 mg/kg ketamine orally as preoperative medication to patients and reported a decrease in the incidence of emergence agitation without a delay in recovery. The effect of ketamine on decreasing the incidence of emergence agitation was confirmed by Abu-Shahwan et al. \[[@B4]\], who injected 0.25 mg/kg ketamine intravenously 10 minutes before the completion of surgery.

Following these studies, in this study, two different doses of ketamine, 0.25 mg/kg and 0.5 mg/kg, was administered 10 minutes before the end of surgery, and the development of emergence agitation, postoperative pain intensity, effects on recovery and incidence of side-effects were compared.

Materials and Methods
=====================

The institutional review board approved this study and the patient\'s guardians provided informed consent after giving a full explanation of the purpose and procedure of this study. Ninety three children, aged between 2-14 years, with American Society of Anesthesiologists (ASA) physical status I-II, who were scheduled to undergo an adenotonsillectomy (or adenoidectomy) under general anesthesia, were enrolled this study. Children with cognitive or developmental disorders were excluded.

The patients were allocated randomly to one of three groups: the control group (administered with a saline solution 10 min before the end of surgery, n = 31), K0.25 group (administered with 0.25 mg/kg of ketamine 10 min before the end of operation, n = 31), and K0.5 group (administered with 0.5 mg/kg of ketamine 10 min before the end of surgery, n = 31). There were no significant differences in age, gender, height, weight, American Society of Anesthesiologists physical status and the length of anesthesia and operation between the three groups ([Table 1](#T1){ref-type="table"}).

Atropine 0.01 mg/kg as a premedication was injected intramuscularly 30 min before the induction of anesthesia. Upon the patients\' arrival into the operating room, the blood pressure, electrocardiogram and pulse oximetry were monitored. Thiopental sodium 5 mg/kg and rocuronium 0.6 mg/kg were administered intravenously, and endotracheal intubation was performed. Anesthesia was maintained with oxygen 1.5 L/min, nitrous oxide 1.5 L/min and sevoflurane at 1.5-3.0 vol%, while controlled ventilation was performed to sustain the endtidal carbon dioxide (ETCO2) between 30 and 35 mmHg. Ten minutes before the end of surgery, the experimental drugs were administered by physicians not participating in the anesthesia, 5 ml in total. The removal time of the mouth gag defined the termination of surgery. At the end of surgery, the administration of sevoflurane and nitrous oxide was discontinued, and manual ventilation was then performed with 100% oxygen at 6 L/min. Pyridostigmine 0.2 mg/kg and glycopyrrolate 0.008 mg/kg were administered to reverse the residual muscle relaxation. Extubation was performed when the patients\' gag reflex was restored and they showed facial grimaces or purposeful-appearing motor movements, and the time period from the end of surgery to the extubation time was recorded. The time span from the attachment of the basic monitoring system until the extubation time was recorded as the duration of anesthesia, whereas the time span between the insertion and removal of the cheek distender was recorded as the duration of surgery. Upon extubation, the patients were transferred to the postanesthesia care unit (PACU), where their emergence agitation was observed by nurses who were blinded to the patients\' groups. Emergence agitation was assessed using a simple four-point scale as follows: 1, asleep; 2, awake but calm; 3, agitated but consolable; and 4, severely agitated and difficult to console. Upon admission to the PACU and at every five minutes, the patients\' emergence behavior was measured and the highest score was recorded during the PACU stay.

The level of nausea was evaluated using a four-point scale to check for the incidence of adverse events as follows: 1, none; 2, nausea only; 3, one episode of vomiting; and 4, more than 2 episodes of vomiting. Recurrent vomiting within 5 minutes was considered to be one single episode. Ondansetron 0.15 mg/kg was provided as an antiemetic drug. If the vomiting was not controlled, repeated administration was performed until the total dose reached 4 mg.

Postoperative pain was assessed using the modified Children\'s Hospital of Eastern Ontario Pain Scale (CHEOPS) and measured upon admission to the PACU, and then pain was measured every five minutes until the time of discharge from the PACU. During the PACU stay, the highest score at any time was recorded.

The agitated children were managed by administering fentanyl 1.0 µg/kg with at least a 10-minute interval between each dose. The drug was discontinued as soon as the symptoms had disappeared.

Modified Aldrete postanesthesia score ([Table 2](#T2){ref-type="table"}) was adopted as the discharge criteria according to which a score \>9 is needed for discharge. Patients who fulfilled the discharge criteria were transferred to the ward unit and the delivery time was recorded.

Statistical analysis was performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). Continuous variables, such as age, height, weight, duration of anesthesia, duration of surgery, duration of extubation after the end of surgery, duration of the PACU stay, and modified CHEOPS were confirmed to follow a normal distribution. Among the variables, duration of extubation, which was reported as the mean ± SD, was analyzed using oneway ANOVA, whereas the other continuous variables were examined using a Kruskal-Wallis test. The categorical variables were compared using a Chi-square test for gender and a Fisher\'s exact test for the ASA, postoperative nausea/vomiting scores, and Emergence Agitation scores. A P value \< 0.05 was considered significant.

Results
=======

Of the 93 patients, one out of each group experienced laryngospasm after extubation and were excluded. No sideeffects such as hallucination or nightmare were observed in the groups administered with ketamine. There were no significant differences in both the time span from the end of surgery until the extubation time and the time span from the arrival at the PACU to the transfer to the ward unit between the three groups. Postoperative pain scores showed significant differences between the three groups, where the scores were significantly different not only between the control group and K0.25 group, between the control group and K0.5 group, but also between the K0.25 and K0.5 group ([Table 3](#T3){ref-type="table"}). No significant differences in the incidence of nausea and vomiting were observed between the groups ([Table 4](#T4){ref-type="table"}).

As for Emergence Agitation scores, there existed significant differences between the control and K0.25 group, and between the control and K0.5 group, whereas no significant differences were detected between the K0.25 and K0.5 group ([Table 5](#T5){ref-type="table"}).

Discussion
==========

Sevoflurane is an inhalational anesthetic that is used widely as pediatric or outpatient anesthesia due to its excellence in hemodynamic stability and low blood solubility, which allows rapid induction and emergence from general anesthesia, and allows control of the depth of anesthesia. However, when sevoflurane is used alone, it is associated with a higher incidence of emergence agitation (EA) in children. The rapid removal of residual anesthetics due to the low blood solubility of sevoflurane has been suggested to cause EA in some patients \[[@B1],[@B5]-[@B10]\]. In addition, a variety of other explanations have been proposed for the etiology of EA. These include the lack of a young child\'s ability to adapt to sudden changes due to an unfamiliar environment after awakening, immature neurological development, anxiety from being separated from their parents, increased pain sensation, sympathetic hyperactivation, etc \[[@B5],[@B10]-[@B12]\].

EA is characterized by self-limiting aggressive agitation that develops in the early phase of awakening from anesthesia at the end of surgery. The term \'Delirium\' is sometimes used to describe such a state \[[@B10]\] but other terms, such as \'agitation\' or \'excitation\', are usually preferred because it is not feasible to evaluate a young child\'s psychological state during emergence. EA can be dangerous to patients, particularly to young children. Patients suffering from EA may harm themselves and dislodge drains or catheters, which will affect the results of surgery. They may inflict a bodily injury on their parents \[caregivers\] or cause a paranoiac accident, which makes the management and monitoring of patients at the PACU difficult \[[@B13]-[@B15]\].

Furthermore, it is difficult to differentiate between pain and EA in young patients because they are poor at expressing their pain and because EA mostly disappears within 15 minutes \[[@B4]\]. Therefore, it is possible to misunderstand self-limiting EA as pain and administer analgesics, such as fentanyl, which creates confusion because of its similarity to the time of pain being controlled.

There have been many attempts to reduce the incidence of EA by propofol \[[@B16],[@B17]\], fentanyl \[[@B18]\], ketamine \[[@B3],[@B4],[@B19]\], ketolorac \[[@B20]\], nalbuphine \[[@B19]\], etc., but the etiology and preventive treatments of EA are still unclear.

Ketamine is a *N-methyl-D-aspartate* (NMDA) receptor antagonist with a strong analgesic effect at a less than anesthesia-inducting dose \[[@B21]\]. It does not cause respiratory depression at small doses (\<1 mg/kg), and has little effect on the heart rate and blood pressure \[[@B22]\]. The incidence of arousal responses, such as nightmares or hallucinations, which restrains the clinical employment of ketamine, is 5-30% at large doses of ketamine \[[@B23]\]. However, the incidence is lower at small doses (\<1 mg/kg) compared to opioids \[[@B24]\]. This study did not encounter a case of hemodynamic instability, or postoperative hallucinations or nightmares.

Kawaraguch et al. \[[@B25]\] reported that the administration of ketamine 1 mg/kg after the induction of anesthesia and the instillation of ketamine 1 mg/kg/hr during surgery in pediatric strabismus surgery succeeded in decreasing EA. Abu-Shahwan et al. \[[@B4]\] showed that an intravenous injection of ketamine 0.25 mg/kg, 10 min before the end of surgery in a dental operation for young children under general anesthesia with sevoflurane decreased the incidence of EA without a delay in recovery. Dalens et al. \[[@B19]\] reported that the intravenous administration of ketamine 0.25 mg/kg or nalbuphine 0.1 mg/kg in general anesthesia with sevoflurane for young children undergoing magnetic resonance imaging was effective in preventing the incidence of EA without delaying awakening or recovery. The present study was designed to compare the effects of small doses of ketamine, 0.25 mg/kg and 0.5 mg/kg, which are hemodynamically stable and have fewer side effects, such as hallucinations or nightmares, on EA and postoperative pain. In contrast to the control group, the K0.25 and K0.5 groups showed a decrease in the incidence of EA and a significant decrease in pain intensity at the PACU. Compared to the K0.25 group, the K0.5 group showed a significant decrease in pain intensity at the PACU but not in the incidence of EA, which suggests that an increase in the ketamine dose was effective in analgesic action, whereas the increase in dose did not affect the incidence of EA. Therefore, it is believed that besides pain, a variety of other causes should make a contribution to the incidence of EA. Hence, a dose of ketamine 0.25 mg/kg alone administered 10 min before the end of surgery would reduce the incidence of EA due to the combined analgesic and sedative action of ketamine. Although ketamine 0.5 mg/kg did not further decrease the incidence of EA compared to ketamine 0.25 mg/kg, a dose of 0.5 mg/kg is recommended for clinical treatment because of the significant analgesic effect at the PACU. Regarding the mechanism of ketamine in reducing the incidence of EA, Lerman et al. \[[@B26]\] suggested that ketamine inhibits the central nervous system effect in ether-linked inhalation anesthetics, which is responsible for increasing the incidence EA after anesthesia with sevoflurane.

The bronchodilating characteristics of ketamine was expected to be effective in preventing the severity of laryngospasm after extubation in young children undergoing an adenotonsillectomy but one from each group experienced laryngospasm after extubation and were excluded. Compared to the control group, the K0.25 and K0.5 groups did not affect the delay in extubation or recovery time, or increase the incidence of nausea and vomiting.

This study had some limitations. First, the three groups did not demonstrate any significant differences in terms of age, even though the study was conducted on children, ranging in age from 2 to 14 years, and was not restricted to preschool children particularly vulnerable to EA. Second, the reason the adenotonsillectomy i.e. severe inflammation in the pharyngeal tonsil or problematic snoring, was not examined, even though postoperative pain, which is greater in case of severe inflammation in the pharyngeal tonsil, can be another variable in the pain scores and the incidence of EA. Further study giving more consideration to such limitations will be needed for more reliable research results.

In conclusion, a dose of 0.25 mg/kg or 0.5 mg/kg of ketamine, administered intravenously 10 min before the end of surgery, successfully reduced the incidence of EA without any particular side-effects or delays in recovery. Although the administration of ketamine 0.5 mg/kg did not decrease the incidence of EA more than that of ketamine 0.25 mg/kg, ketamine 0.5 mg/kg had significant analgesic effects on postoperative pain at the PACU. Therefore, 0.5 mg/kg ketamine, which decreases the incidence of EA and has postoperative analgesic effect, is recommended as the appropriate dose.
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Demographic Data
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Values are median (25%, 75%). There are no significant differences among the three groups.
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The Modified Aldrete Postanesthesia Score
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Modified CHEOPS (Children\'s Hospital of Eastern Ontario Pain Scale)
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Extubation time, Delivery Time, and PONV (Postoperative Nausea, Vomiting)
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Values of extubation time are mean ± SD. Values of delivery time are median (25%, 75%). There are no significant differences among the three groups. PONV scale : 1 = none, 2 = retching, 3 = one episode of vomit, 4 = multiple episode of vomit.
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Pain Score (Modified CHEOPS), and Agitation Score

![](kjae-58-440-i005)

Values of modified CHEOPS are median (25%, 75%). Agitation score : 1 = asleep, 2 = awake and calm, 3 = agitated but consolable, 4 = severely agitated and inconsolable. ^\*^P \< 0.05 compared with the Group C, ^†^P \< 0.05 compared with the Group K0.25.
